Revolution Medicines is a clinical-stage biopharmaceutical company focused on cancers driven by RAS pathway mutations. Its pipeline centers on RAS(ON) inhibitors designed to target active RAS proteins that fuel many solid tumors. The company partners with oncology investigators and clinical sites while remaining largely pre-commercial, with value tied to late-stage development of these targeted therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -247.8 | — |
| Q3 2025 | 0 | — | -305.2 | — |
| Q4 2025 | 0 | — | -364.9 | — |
| Q1 2026 | 0 | — | -453.8 | — |
| Q2 2026 | 0 | — | -644.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Roper Technologies, Inc. (ROP), Vodafone Group Public Limited Company (VOD), JD.com, Inc. (JD), Ferrovial N.V. (FER), Elbit Systems Ltd. (ESLT), Royalty Pharma plc (RPRX)